Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Can-Fite Biopharma Ltd ADR (NY: CANF )

2.120 +0.070 (+3.41%)
Official Closing Price Updated: 8:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Can-Fite Biopharma Ltd ADR

< Previous 1 2 3 Next >
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Can Fite Biofarma: Q4 Earnings Insights
Via Benzinga
Recap: Can Fite Biofarma Q3 Earnings
Via Benzinga
Recap: Can Fite Biofarma Q1 Earnings
Via Benzinga
CANF Stock Earnings: Can Fite Biofarma Beats EPS, Beats Revenue for Q4 2023
CANF stock results show that Can Fite Biofarma beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Why Is Liver Cancer Focused Can-Fite BioPharma Stock Trading Higher Today?
Can-Fite BioPharma Ltd (NYSE: CANF) announced that a patient who participated in the Phase 2 Liver Cancer Study and was treated with namodenoson had a complete response and overall survival of  
Via Benzinga
Matson To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time for another dive into the biggest pre-market stock movers as we see what's moving the market on Thursday morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Can-Fite Revenue FY22 Revenue Declines 4.7%, Here Is What You Need To Know
Can-Fite BioPharma Ltd. (AMEX:CANF) (TASE:CANF) revenues for the year ended December 31, 2022 were $810,000, a decrease of $43,000, or 4.7%, compared to revenues of $853,000 during the twelve months... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday, 40 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  During Friday, 48 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 22 companies hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 35 companies reached new 52-week lows. 
Via Benzinga
Can-Fite's Namodenoson Increases Survival For Most Severe Patients With Advanced Liver Cancer
Via Benzinga
Multiple Shots On Goal: Can-Fite’s Late-Stage Clinical Pipeline Hits Positive Results
By Ernest Dela Aglanu, Benzinga 
Via News Direct
Multiple Shots On Goal: Can-Fite's Late-Stage Clinical Pipeline Hits Positive Results
Multiple countries are approving Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) ’s Namodenoson for compassionate use in patients with advanced liver cancer. 
Via Benzinga
Meet This BioPharma Company With Several Exciting Drugs In Advanced Clinical Trials
Sign up for this week’s All Access giveaway here!  Pnina Fishman, Ph.D., CEO of Can-Fite BioPharma (NYSE: CANF), was a guest on Benzinga’s All Access on Nov 4, 2022. 
Via Benzinga
This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers
The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up.   
Via Benzinga
Smoking Pot Makes You 55% Less Likely To Develop This Deadly Cancer
Marijuana users have 55% fewer chances of developing, one of the most common malignancies worldwide - hepatocellular carcinoma (HCC), according to a study  
Via Benzinga
Industry Analysts Seemingly Sing Praises For This Stock After Phase III Trial Results
Psoriasis is a common chronic disease mediated by the immune system. It’s characterized by red, scaly patches that form on the skin. Psoriasis affects more than 3% of the U.S. adult population — over... 
Via Benzinga
Boeing, PriceSmart And 80 Biggest Movers From Yesterday
Gainers Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share. 
Via Benzinga
Why Is Canoo Surging By 80%? 52 Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Alibaba, Zoom Video And 76 Biggest Movers From Yesterday
Gainers Kaspien Holdings Inc. (NASDAQ: KSPN) shares climbed 161.9% to close at $6.81 on Monday on heavy volume amid mention of the stock on social media. 
Via Benzinga
Akerna Shares Dip 53%, Here's 78 Biggest Movers From Yesterday
Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.